Drug Shortage Report for TAZORAC
| Report ID | 118029 |
| Drug Identification Number | 02230785 |
| Brand name | TAZORAC |
| Common or Proper name | tazarotene |
| Company Name | ALLERGAN INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | TAZAROTENE |
| Strength(s) | 0.1% |
| Dosage form(s) | GEL |
| Route of administration | TOPICAL TOPICAL |
| Packaging size | 30g |
| ATC code | D05AX |
| ATC description | ANTIPSORIATICS FOR TOPICAL USE |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2020-07-27 |
| Actual start date | 2020-08-10 |
| Estimated end date | 2021-04-20 |
| Actual end date | 2021-04-14 |
| Shortage status | Resolved |
| Updated date | 2021-04-15 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Company contact information; Telephone number: 800-668-6424 Email address: MR-GENERAL_INQUIRY@allergan.com Website address: allergan.ca Postal address: 500-85 Enterprise Blvd, Markham, Ontario, L6G 0B5 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v14 | 2021-04-15 | French | Compare |
| v13 | 2021-04-15 | English | Compare |
| v12 | 2021-03-04 | French | Compare |
| v11 | 2021-03-04 | English | Compare |
| v10 | 2021-01-19 | French | Compare |
| v9 | 2021-01-19 | English | Compare |
| v8 | 2020-09-03 | French | Compare |
| v7 | 2020-09-03 | English | Compare |
| v6 | 2020-08-11 | English | Compare |
| v5 | 2020-08-10 | French | Compare |
| v4 | 2020-08-10 | English | Compare |
| v3 | 2020-07-28 | English | Compare |
| v2 | 2020-06-16 | French | Compare |
| v1 | 2020-06-16 | English | Compare |
Showing 1 to 14 of 14